Related Experiment Video

Updated: Jun 18, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

Natriuretic peptides and the genomics of left-ventricular hypertrophy

Daniel L Dries1

  • 1Penn Cardiovascular Institute and Cardiovascular Division, Heart Failure and Transplant Group, Heart Vascular Center, 3400 Civic Center Boulevard, Philadelphia, PA 19104-4283, USA. daniel.dries@uphs.upenn.edu

Heart Failure Clinics
|December 1, 2009
PubMed

Insights

Genetic factors significantly influence left-ventricular hypertrophy (LVH) susceptibility, contributing to variations in left ventricular mass (LVM) beyond known risks like hypertension and obesity. Understanding these genetic determinants is crucial for identifying at-risk individuals and developing new treatments.

Area of Science:

  • Cardiology
  • Genetics
  • Public Health

Background:

  • Left-ventricular hypertrophy (LVH) is a major predictor of cardiovascular disease.
  • Hypertension and obesity explain only a portion of the variability in left ventricular mass (LVM).
  • Inter-individual differences in LVH susceptibility suggest a significant genetic component.

Purpose of the Study:

  • To investigate the genetic basis of inter-individual variability in left ventricular mass (LVM).
  • To identify genetic determinants influencing susceptibility to left-ventricular hypertrophy (LVH).

Main Methods:

  • This study focuses on analyzing the genetic factors contributing to LVM variations.
  • Investigated the genetic underpinnings of susceptibility to LVH.

Main Results:

  • A substantial genetic basis exists for individual differences in susceptibility to LVH.
  • Genetic factors play a key role in determining left ventricular mass (LVM).

Conclusions:

  • Elucidating genetic determinants of LVH is critical for public health.
  • Identifying genetic factors can lead to targeted interventions for high-risk individuals.
  • This research may reveal novel therapeutic targets for preventing and treating LVH.

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...